Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
Pratteln, Switzerland, May 20, 2025 – Santhera Pharmaceuticals (SIX: SANN) today announces that its shareholders approved all motions by the Board of Directors at the Annual General Meeting (AGM) held today in Pratteln, Switzerland, with a large majority. Participating shareholders represented a total of 5,073,050 shares or 37.5% of the Company’s share capital.
Approval of the 2024 Annual Report and discharge of corporate bodies
The shareholders approved the Annual Report, the annual financial statements and the consolidated financial statements for 2024, as well as the appropriation of the annual result and its offset against free reserves. Furthermore, the shareholders granted discharge to the members of the Board of Directors and Executive Management for the financial year 2024.
Approval of conditional capital for employee participation
The shareholders approved to amend the Articles of Incorporation to increase the conditional capital for employee participation by CHF 63,000 to CHF 111,280.20.
Election of new Member and re-election of Members of the Board of Directors and the Nomination & Compensation Committee
Shareholders re-elected Thomas Meier, Philipp Gutzwiller and Bradley C. Meyer, to serve another one-year term on the Board of Directors. In addition, shareholders re-elected Thomas Meier as Chairman of the Board of Directors and approved the election of Melanie Rolli as a Member of the Board. As members of the Nomination & Compensation Committee, the shareholders confirmed Thomas Meier and Bradley C. Meyer (Committee Chairman).
Compensation Report and remuneration for Board and Executive Management approved
In a consultative vote, the shareholders endorsed the Compensation Report 2024. In separate binding votes, Santhera’s shareholders agreed to the compensation for members of the Board of Directors (maximum total amount of fixed compensation covering the period from the 2025 AGM to the 2026 AGM) and for the members of the Executive Management (maximum total amount of fixed compensation for 2026, variable cash compensation for 2024 and variable compensation in the form of Share Appreciation Rights and Performance Share Units for 2025).
AGM documents
Details and accompanying explanations on all motions, which were all approved by the AGM, can be viewed in the “Invitation to the Annual General Meeting of Shareholders”, available on Santhera’s website at /share-bondholder-meetings. From the end of next week, the minutes of the 2025 AGM will also be available.
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA), in China by the National Medical Products Administration (NMPA) and Hong Kong by the Department of Health (DoH). Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals and for China and certain countries in Southeast Asia to Sperogenix Therapeutics. For further information, please visit .
AGAMREE® is a trademark of Santhera Pharmaceuticals.
For further information please contact:
Catherine Isted, Chief Financial Officer:
ICR Healthcare:
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #
Attachment
